5334-26-9

Basic information

• Product Name: 6-METHYLSULFANYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL
• Synonyms: 6-METHYLSULFANYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL;6-methylsulfanyl-1,2-dihydropyrazolo[3,4-d]pyrimidin-4-one;6-Methylsulfanyl-4-hydroxy-1H-pyrazolo[3,4-d]pyrimidine
• CAS NO: 5334-26-9
• Molecular Formula: C₆H₆N₄OS
• Molecular Weight: 182.203
• Mol File: 5334-26-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 340.6°Cat760mmHg
• Flash Point: 159.8°C
• Appearance: /
• Density: 1.78g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.772
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-METHYLSULFANYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHYLSULFANYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL(5334-26-9)
• EPA Substance Registry System: 6-METHYLSULFANYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL(5334-26-9)

Safety Data

• Hazardous Substances Data: 5334-26-9(Hazardous Substances Data)

Usage

General Description

6-METHYLSULFANYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL is a chemical compound with the molecular formula C7H7N5OS. It belongs to the pyrazolopyrimidine family and is a derivative of pyrazolo[3,4-d]pyrimidin-4-ol. 6-METHYLSULFANYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL is known for its potent biological activities and is being researched for its potential pharmaceutical applications. It is a sulfur-containing compound, and the presence of the methyl group adds to its structural complexity and potential for diverse chemical interactions. Its properties and potential applications make it an interesting target for further research and development in the field of medicinal chemistry.

InChI:InChI=1/C6H6N4OS/c1-12-6-8-4-3(2-7-10-4)5(11)9-6/h2H,1H3,(H2,7,8,9,10,11)

Upstream product

• 5444-29-1 6-methylsulfanyl-1⁽²⁾H-pyrazolo[3,4-d]pyrimidin-4-ylamine 
• 24521-76-4 6-thioxo-1,5,6,7-tetrahydropyrazolo<3,4-d>pyrimidin-4-one 
• 623-11-0 1-methyl-4-nitrosobenzene 
• 74-88-4 methyl iodide 
• 85426-79-5 4-chloro-6-methylmercapto-1H-pyrazolo[3,4-d]pyrimidine 
• 24521-76-4 4-hydroxy-6-mercapto-1H-pyrazolo[3,4-d]pyrimidine 

Downstream Products

• 85426-79-5 4-chloro-6-methylmercapto-1H-pyrazolo[3,4-d]pyrimidine 
• 594865-02-8 benzyl-(6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-04-0 benzyl-(1-methyl-6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-23-3 (3-bromo-phenyl)-(6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-25-5 (3-methoxy-phenyl)-(6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-30-2 (3-methoxy-phenyl)-(1-methyl-6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-24-4 (3-fluoro-phenyl)-(6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-28-8 (3-fluoro-phenyl)-(1-methyl-6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-26-6 (3-bromo-phenyl)-(1-methyl-6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-05-1 benzyl-(1-isopropyl-6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-29-9 (3-fluoro-phenyl)-(1-isopropyl-6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-31-3 (1-isopropyl-6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-(3-methoxy-phenyl)-amine 
• 594865-09-5 benzyl-(6-methanesulfonyl-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-08-4 benzyl-(6-methanesulfonyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 

Relevant articles and documents

Synthesis and biological evaluations of pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 inhibitors

A series of 1,4,6-trisubstituted pyrazolo[3,4-d]pyrimidines 15-19, 30-38 capable of selectively inhibiting CDK2 activity were synthesized by derivatization at C-4, C-6 and N-1 with various amines and lower alkyl groups. For above synthetic compounds, biological evaluation was carried out and structure-activity relationship was examined. In our series, 4-anilino compounds exhibited better CDK2 inhibitory activity and antitumor activity compared to 4-benzyl compounds. The compounds 33a,b having a 3-fluoroaniline group at C-4 showed comparable or superior CDK2 inhibitory activity to those of olomoucine and roscovitine as reference compounds. In general, the unsubstituted compounds (30a,b, 33a,b, 36a,b) at N-1 possessed higher potency than the substituted compounds (32a,b, 34a,b) for the CDK2 inhibitory activity. As for EGFR inhibitory activity, most compounds didnot have a significant activity. The compounds 32a,b exhibited potent cell growth inhibitory activity against human cancer cell lines, but their CDK2 inhibitory activities were slightly poorer than olomoucine.